The therapeutic potential of novel antiangiogenic therapies.
Promising new antiangiogenic strategies are emerging for the treatment of cancer. Numerous candidate drugs that target vascular endothelial growth factor, vascular endothelial growth factor receptors, integrins, matrix metalloproteinases and other blood vessel targets are being developed and tested in clinical trials. This review highlights the numerous drugs in clinical trials and expands on potential new approaches to inhibiting angiogenesis. These approaches include gene therapy, vaccine strategies and antiangiogenic radioligands. New insight has been gained from completed Phase III trials with antiangiogenic drugs and some of the major obstacles include design of trials, dosing, toxicities and resistance. This review will discuss these barriers and methods by which they can be overcome.
Scappaticci
Frank A
FA
2761 S. Norfolk St., San Mateo, CA 94403, USA. anthon@leland.stanford.edu
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D019496:Cancer Vaccines / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data / Q000639:trends; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D019496:Cancer Vaccines